- Direction
- Unknown
- Own history
- —
- Peers
- 61th
- Persistence
- TRANSIENT
· Pharmaceutical Preparations
RESEARCH SNAPSHOTBIOMARIN PHARMACEUTICAL INC's latest supported as-filed period reports revenue of $989.7M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
Separate current dimensions—not a universal score or investment ranking.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 422.97% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 2.91% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 16.99% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 19.91% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 180.11% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 79.51% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Inventory increased 33.0%; Inventory / revenue moved 1774 bp higher.
2 evidence-backed componentsThis cluster groups 3 independently calculated changes: Revenue increased 19.9%; Operating margin moved 2234 bp lower; Operating income decreased 59.9%.
3 evidence-backed componentsThis cluster groups 2 independently calculated changes: Gross margin moved 231 bp lower; Operating margin moved 2234 bp lower.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Cash & equivalents decreased 28.0%; Operating cash flow decreased 9.3%.
2 evidence-backed componentsThis cluster groups 2 independently calculated changes: Capital expenditure increased 68.5%; Capex / revenue moved 84 bp higher.
2 evidence-backed componentsCurrent liabilities changed +143.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
BMRN · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001048477-26-000019SEC ↗4Oct 1, 2026Period Sep 30, 20260001628280-26-064272SEC ↗8-KSep 30, 2026Period Sep 24, 20260001628280-26-063981SEC ↗8-KSep 15, 2026Period Sep 15, 20260001628280-26-061973SEC ↗4Sep 14, 2026Period Sep 10, 20260001628280-26-061940SEC ↗8-KSep 14, 2026Period Sep 10, 20260001628280-26-061717SEC ↗4Sep 3, 2026Period Sep 2, 20260001628280-26-060572SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Sep 30, 2026Filed Oct 1, 2026 | Friberg Gregory REVP, Chief R&D Officer | Tax WithholdingDirect | 4,086 | $60 | $245,160 | Form 4 ↗ |
| Sep 10, 2026Filed Sep 14, 2026 | Plenge Robert MDirector | Grant Or AwardDirect | 6,140 | $0 | $0 | Form 4 ↗ |
| Sep 2, 2026Filed Sep 3, 2026 | Davis George EricEVP, Chief Legal Officer | Open Market SaleDirect | 17,557 | $66 | $1.2M | Form 4 ↗ |
| Jun 2, 2026Filed Jun 4, 2026 | Countouriotis AthenaDirector | Grant Or AwardDirect | 7,490 | $0 | $0 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value 11.21% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 20.91% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 7.65% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Total assets changed +57.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed +33.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Working capital / assets changed -2217 basis points from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating income changed -59.9% from the comparable as-filed period.
Operating margin changed -2234 basis points from the comparable as-filed period.
Cash & equivalents changed -28.0% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001193125-26-377696